Beta Bionics, Inc. Common Stock (BBNX) Stock Forecast & Price Target
Beta Bionics, Inc. Common Stock · NASDAQ
$15.98+0.13 (+0.82%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 9 firms covering Beta Bionics, Inc. Common Stock, 6 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $11.00 to $40.00 (about 3.6x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $22.11 sits 38% above the current $15.98. The rating mix has stayed broadly stable, with Buy-side ratings easing from 8 to 6 over recent months. On the fundamentals, the Street sees revenue growth near 33% this year and 35% next, consensus EPS building from about $-0.53 next quarter toward $-2.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS9 ratings
Moderate Buy
Strong Buy00%
Buy667%
Hold333%
Sell00%
Strong Sell00%
Based on 9 analysts giving stock ratings to Beta Bionics, Inc. Common Stock.
As of Jul, 6 of 9 firms rate BBNX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BBNX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.53
Range $-0.57 – $-0.49 · 3 analysts · +60% YoY
Next period, 3 analysts expect Beta Bionics, Inc. Common Stock to earn $-0.53 a share (range $-0.57 – $-0.49), versus $-0.33 a year earlier. Full-year consensus is $-2.11, growing to $-2.39 the year after.
REVENUE · NEXT QUARTER
$35.0M
Range $33.7M – $36.0M · 3 analysts · +29% YoY
Revenue is expected to reach $35.0M (range $33.7M – $36.0M), +29.0% year-over-year. Full-year consensus is $133.3M, rising to $179.5M next year.
Top analysts covering Beta Bionics, Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BBNX.
#1
Jonathan Block
Stifel · Rank #172
Buy
$20.00+25.2% to target
Overall win rate
42%
+ Follow
#2
Frank Takkinen
Lake Street · Rank #327
Buy
$40.00+150.3% to target
Overall win rate
26%
+ Follow
#3
Matt O'Brien
Piper Sandler · Rank #356
Buy
$32.00+100.3% to target
Overall win rate
25%
+ Follow
#4
David Roman
Goldman Sachs
Buy
$19.00+18.9% to target
Coverage
—
+ Follow
#5
Richard Newitter
Truist Securities
Buy
$22.00+37.7% to target
Coverage
—
+ Follow
BBNX stock forecast FAQ
What is BBNX's average 12-month price target?+
The 9 analysts with a live target average $22.11 for Beta Bionics, Inc. Common Stock over the next 12 months, ranging from a $40.00 high to a $11.00 low.
Is BBNX stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 9 analyst ratings, 6 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BBNX?+
The Street-high target is $40.00 (Lake Street), and the Street-low is $11.00 (B of A Securities). The average of all 9 active targets is $22.11.
How many Wall Street analysts cover BBNX?+
9 analysts have an active rating on Beta Bionics, Inc. Common Stock, and 9 firms carry a live 12-month price target.
Who is the most accurate analyst covering BBNX?+
Among analysts who currently cover BBNX, Jonathan Block of Stifel has the strongest overall Quantellect track record (Rank #172). Their current call is Buy with a $20.00 target.
What is Beta Bionics, Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $-0.53 per share (range $-0.57 – $-0.49) across 3 analysts. Full-year EPS is projected at $-2.11, rising to $-2.39 the following year.
How much revenue is Beta Bionics, Inc. Common Stock expected to report next quarter?+
Consensus revenue is $35.0M (range $33.7M – $36.0M). Full-year revenue is projected at $133.3M, growing to $179.5M next year.
Have analysts been upgrading or downgrading BBNX lately?+
As of Jul, 6 of 9 firms rate BBNX a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BBNX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
